A Study Of PF-04449913 Administered Alone In Select Solid Tumors

ClinicalTrials.gov ID: NCT01286467

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01286467. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF 04449913, AN ORAL HEDGEHOG INHIBITOR, ADMINISTERED AS SINGLE AGENT IN SELECT SOLID TUMORS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select solid tumors.

Study identification

NCT ID: NCT01286467
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 23 participants

Conditions and interventions

Conditions

Solid Tumors

Interventions

PF-04449913 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 11, 2011 (Actual)
Primary completion: May 10, 2012 (Actual)
Completion: Dec 28, 2012 (Actual)
Last update posted: Mar 6, 2024

2011 – 2012

United States locations

U.S. sites: 9
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Keck Hospital of University of Southern California	Los Angeles	California	90033	—
Los Angeles County-University of Southern California Medical Center	Los Angeles	California	90033	—
University of Southern California/Norris Comprehensive Cancer Center/Investigational Drug Service	Los Angeles	California	90033	—
University of Southern California/Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
Anschutz Cancer Pavilion	Aurora	Colorado	80045	—
University of Colorado Denver	Aurora	Colorado	80045	—
University of Colorado Hospital	Aurora	Colorado	80045	—
Brigham and Women's Hospital (BWH)	Boston	Massachusetts	02115	—
Dana-Farber Cancer Institute (DFCI)	Boston	Massachusetts	02115	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01286467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 6, 2024 · Synced Nov 15, 2026